Notoginsenoside R1 (NGR1) regulates the AGE-RAGE signaling pathway by inhibiting RUNX2 expression to accelerate ferroptosis in breast cancer cells

Wenxin Li, Yan Guo, Zhuangyu Xu, Fubo Li, Yi Dong, Fan XuAging 2024 · DOI

TL;DR

This study reveals that Notoginsenoside R1 (NGR1), a compound from ginseng, can induce ferroptosis (a form of programmed cell death) in breast cancer cells by inhibiting the RUNX2 protein. This inhibition, in turn, suppresses the AGE-RAGE signaling pathway, offering a potential new therapeutic strategy for breast cancer.

What Problem Does This Paper Address?

Breast cancer remains a leading cause of death among women, with metastasis being a major contributor to mortality. While advancements in treatment have improved survival rates, there's a continuous need for novel therapeutic targets and strategies. Ferroptosis, a distinct mode of cell death driven by iron accumulation and lipid peroxidation, has emerged as a promising avenue for cancer therapy. However, the specific mechanisms by which natural compounds like NGR1 might induce ferroptosis in breast cancer cells, and their precise molecular targets, were not well understood. This paper aims to elucidate how NGR1 influences breast cancer progression, specifically by investigating its role in ferroptosis and identifying its molecular targets.

Methods

The researchers employed a multi-pronged approach to investigate NGR1's effects:

  • Bioinformatics Analysis: They utilized public databases (GEO, CTD, STRING, GEPIA2) to identify potential NGR1 targets and enriched signaling pathways in breast cancer. This involved Principal Component Analysis (PCA), volcano plots, heatmaps, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses, and protein-protein interaction (PPI) network construction.
  • Molecular Docking: To predict the binding affinity between NGR1 and its identified target, molecular docking simulations were performed.
  • Cell Culture and Transfection: Various human breast cancer cell lines (MDA-MB-231, SK-BR-3, MCF-7, etc.) were cultured. They then used transfection techniques to either overexpress or downregulate the expression of the key target protein, RUNX2.
  • Cell Viability Assays: The Cell Counting Kit-8 (CCK8) assay was used to measure the proliferation and viability of breast cancer cells treated with NGR1, and to assess the impact of RUNX2 manipulation on NGR1's efficacy.
  • Biochemical Assays: Measurements of intracellular Fe<sup>2+</sup> and malondialdehyde (MDA) were conducted to assess oxidative stress and lipid peroxidation, key indicators of ferroptosis.
  • Molecular Biology Techniques:
    • Western Blotting: Used to detect and quantify protein expression levels of RUNX2, AGE, RAGE, and various ferroptosis-related proteins (ACSL4, COX2, FIH1, GPX4, NOX1, PTGS2).
  • Quantitative Polymerase Chain Reaction (qPCR): Used to measure the mRNA expression levels of RUNX2.
  • Electron Microscopy: Employed to visualize and assess the ultrastructural changes in mitochondria within breast cancer cells following NGR1 treatment and RUNX2 manipulation, as mitochondrial integrity is crucial in ferroptosis.

Datasets

  • GSE205185 Dataset: Downloaded from the GEO database, this dataset was used for differential gene expression analysis and pathway enrichment.
  • TCGA Database: Utilized via the GEPIA2 database to explore the expression of identified intersecting genes in breast cancer patients.
  • CTD Database: Used to download NGR1 target information.
  • STRING Database: Employed for constructing protein-protein interaction networks.
  • PubChem Compound Database: Provided the molecular structure of NGR1.
  • PDB (Protein Data Bank): Provided the 3D coordinates for the RUNX2 protein.

No new benchmarks were introduced; standard public datasets were used for analysis.

Key Insights and Ideas

  • NGR1's Dual Role: NGR1 not only inhibits breast cancer cell proliferation but also actively induces ferroptosis, a less-explored mechanism of cell death in this context.
  • RUNX2 as a Central Mediator: The study strongly implicates RUNX2 as a key downstream target of NGR1. NGR1's ability to inhibit RUNX2 expression appears to be the linchpin for its anti-cancer effects.
  • AGE-RAGE Pathway Link: The research establishes a critical connection between NGR1, RUNX2, and the AGE-RAGE signaling pathway, suggesting that NGR1's action on RUNX2 disrupts this pro-cancer pathway.
  • RUNX2's Protective Role: Overexpressing RUNX2 in cancer cells can counteract the ferroptosis-inducing effects of NGR1, highlighting RUNX2's potential role in promoting cancer cell survival against ferroptotic stimuli.
  • Differential Sensitivity: The observation that MDA-MB-231 cells (with higher baseline RUNX2) are more strongly inhibited by NGR1 than SK-BR-3 cells (with lower baseline RUNX2) suggests that RUNX2 expression levels might predict response to NGR1 therapy.

Key Results

  • NGR1 Inhibits RUNX2: NGR1 treatment significantly reduced both mRNA and protein levels of RUNX2 in breast cancer cell lines.
  • NGR1 Induces Ferroptosis: NGR1 treatment led to increased intracellular Fe<sup>2+</sup> and MDA levels, indicative of ferroptosis. Electron microscopy revealed mitochondrial damage, a hallmark of ferroptosis.
  • NGR1 Modulates Ferroptosis Proteins: NGR1 treatment upregulated pro-ferroptotic proteins (ACSL4, COX2, NOX1) and downregulated anti-ferroptotic proteins (FIH1, GPX4).
  • RUNX2 Reverses NGR1 Effects: Overexpression of RUNX2 partially rescued breast cancer cells from NGR1-induced proliferation inhibition and ferroptosis. Conversely, RUNX2 knockdown enhanced NGR1's inhibitory effects.
  • AGE-RAGE Pathway Inhibition: NGR1 treatment, particularly in conjunction with RUNX2 downregulation, suppressed the expression of AGE and RAGE proteins, indicating inhibition of the AGE-RAGE signaling pathway.

Limitations and Future Work

  • In Vitro Focus: The study was conducted entirely in vitro. The authors acknowledge the need for in vivo animal experiments to validate these findings and assess NGR1's efficacy and safety in a more complex biological system.
  • Unexplored Regulatory Relationships: While the study identified a link between NGR1, RUNX2, and the AGE-RAGE pathway, the precise regulatory mechanisms and potential reverse validation experiments were not performed.
  • Mechanism of RUNX2 Regulation: The exact molecular mechanism by which NGR1 downregulates RUNX2 expression remains to be fully elucidated.
  • Clinical Translation: Further research is needed to explore the therapeutic potential of NGR1 and RUNX2 as a target for clinical application in breast cancer treatment. Investigating the interplay with other signaling pathways and potential drug resistance mechanisms would also be valuable.

Summary updated

Abstract

Ferroptosis is a new way of cell death, and stimulating the process of cell ferroptosis is a new strategy to treat breast cancer. NGR1 has good anti-cancer activity and is able to slow the progression of breast cancer. However, NGR1 has not been reported in the field related to ferroptosis. By searching the online database for potential targets of NGR1 and the breast cancer disease database, among 11 intersecting genes we focused on Runt-related transcription factor 2 (RUNX2), which is highly expressed in breast cancer, and KEGG pathway enrichment showed that the intersecting genes were mainly enriched in the AGE (advanced glycosylation end products)-RAGE (receptor of AGEs) signaling pathway. After that, we constructed overexpression and down-regulation breast cancer cell lines of RUNX2 <i>in vitro</i>, and tested whether NGR1 treatment induced ferroptosis in breast cancer cells by regulating RUNX2 to inhibit the AGE-RAGE signaling pathway through phenotyping experiments of ferroptosis, Western blot experiments, QPCR experiments, and electron microscopy observation. The results showed that NGR1 was able to inhibit the expression level of RUNX2 and suppress the AGE/PAGE signaling pathway in breast cancer cells. NGR1 was also able to promote the accumulation of Fe<sup>2+</sup> and oxidative damage in breast cancer cells by regulating RUNX2 and then down-regulating the expression level of GPX4, FIH1 and up-regulating the expression level of ferroptosis-related proteins such as COX2, ACSL4, PTGS2 and NOX1, which eventually led to the ferroptosis of breast cancer cells.
BibTeX
@inproceedings{li2024notoginsenoside,
  author = {Wenxin Li and Yan Guo and Zhuangyu Xu and Fubo Li and Yi Dong and Fan Xu},
  title = {{Notoginsenoside R1 (NGR1) regulates the AGE-RAGE signaling pathway by inhibiting RUNX2 expression to accelerate ferroptosis in breast cancer cells}},
  booktitle = {Aging},
  year = {2024},
  doi = {10.18632/aging.205940},
}
Figure